Latest / Intellectual Medicine / Repurposed Drugs for Prostate Cancer: What Your Oncologist Will Never Tell You

Transcript

Repurposed Drugs for Prostate Cancer: What Your Oncologist Will Never Tell You · Intellectual Medicine

• 0:00
  Now repurposed drugs, it's also known as off label prescribing.
• 0:03
  It's part of medicine forever. Good doctors know how to apply
• 0:07
  it. Repurposed drug is a whole
• 0:09
  nother level. Now we're talking about cancer.
• 0:14
  And I can tell you that many doctors are afraid to enter the
• 0:17
  arena because the oncologist dominated.
• 0:21
  And you should be cautious as a doctor entering the arena.
• 0:24
  You don't want to cause harm. You do not want to direct them
• 0:27
  away from therapy. That may be incredibly
• 0:30
  beneficial, which is why I'm so boldly proclaiming that you
• 0:34
  should read my book if you're a man with a prostate or you know
• 0:38
  somebody who has a prostate. So you're informed and prepared
• 0:42
  because it comes at your past. Hey gang.
• 0:49
  So we're going to talk about repurposed drugs for prostate
• 0:52
  cancer. Now before we talk about
• 0:55
  repurposed drugs for prostate cancer, we have to reflect upon
• 0:59
  why. Why would someone do that?
• 1:03
  So let's back, let's back it up to the conventional therapy.
• 1:07
  You guys know, I'm a, I'm a therapeutic agnostic.
• 1:11
  If there's something out there that is safe and effective and
• 1:14
  can help my patients, I'm on board.
• 1:18
  I don't care where it comes from.
• 1:19
  You've heard of big pharma. Everybody's nervous about that.
• 1:22
  There's something else called big Supplementa.
• 1:25
  You show me a colossal financial motive and I'll show you a
• 1:30
  potential to alter judgement, decision making and treatment
• 1:35
  pathways. So it is with prostate cancer
• 1:38
  and conventional therapy. Why repurpose drugs?
• 1:41
  Why the Petteruti protocol? Because their treatment is
• 1:45
  awful. Because the studies have a
• 1:48
  publication bias. Now that means that if a
• 1:52
  pharmaceutical company or another entity is researching
• 1:56
  something and the result is bad, they don't publish it.
• 2:00
  They control the publication pathway.
• 2:03
  This is called publication bias. There's another lesser known
• 2:08
  bias that is harder to uncover, and it is called interpretive
• 2:13
  bias. I'll give you an example.
• 2:16
  They'll talk about this fabulous new conventional therapy.
• 2:20
  I love to pick on Plovidco because it's so easy a target,
• 2:25
  right? This is a drug that cost about a
• 2:26
  quarter $1,000,000 and it's for late stage prostate cancer.
• 2:30
  And the studies demonstrated significant extension of
• 2:35
  survival headline. That's great, but wait.
• 2:41
  Significant. Meant for months, Statistically
• 2:44
  significant. Clinically worth the price of
• 2:47
  admission plus the side effects, plus the treatment itself.
• 2:51
  Harsh. Harsh.
• 2:53
  The original studies on chemotherapy for prostate cancer
• 2:57
  had the same conclusion. Significant extension of
• 3:01
  survival. Two months. 2 freaking months.
• 3:06
  Two months of vomiting. Hair shed.
• 3:09
  Really, people? So let's not be so dissuaded.
• 3:13
  Let's accept the fact that life will come to its end.
• 3:19
  I'm not pushing for it. I want you to live to be past
• 3:22
  100, but do not let them peddle toxicity to you for the specious
• 3:30
  hope of a couple of weeks of being on the planet.
• 3:33
  So this is where we step in now. Repurposed drugs.
• 3:37
  It's also known as off label prescribing.
• 3:40
  It's part of medicine forever. Good doctors know how to apply
• 3:44
  it and we've used this forever. And a depressant drug,
• 3:49
  amitriptyline, has great utility with chronic headache.
• 3:53
  Doxycycline has great utility with inflammatory issues.
• 3:56
  Sometimes rheumatologists will use it off label.
• 4:00
  Repurposed drug is a whole nother level.
• 4:03
  Now we're talking about cancer, and I can tell you that many
• 4:07
  doctors are afraid to enter the arena because the oncologist
• 4:12
  dominated. And you should be cautious as a
• 4:14
  doctor entering the arena. You don't want to cause harm.
• 4:18
  You do not want to deviate a patient, or I should say, direct
• 4:22
  them away from therapy. That may be incredibly
• 4:24
  beneficial, which is why I'm so boldly proclaiming that you
• 4:28
  should read my book if you're a man with a prostate or you know
• 4:32
  somebody who has a prostate. So you're informed and prepared
• 4:36
  because it comes at you fast. All right, So what are my
• 4:39
  repurposed drugs and how do we arrive at them?
• 4:42
  That's a good question. How do you pick them?
• 4:45
  No, you don't Google them on AI and just spit them out.
• 4:49
  First you have to do depth of research.
• 4:52
  So one criteria. It's got to be safe.
• 4:56
  Prostate cancer is not something that you obliterate and then
• 5:00
  don't worry about. It's something you suppress and
• 5:03
  maintain the suppression. So it's got to be safe.
• 5:07
  It has to have evidence of benefit against prostate cancer
• 5:10
  specific, and that means in vitro lab evidence.
• 5:15
  That's nice. Not good enough.
• 5:17
  If the only evidence is in a cell and a Petri dish, it's not
• 5:21
  good enough. Another level would be
• 5:24
  xenografts on animals. That's better.
• 5:28
  A xenograft is when you take a human prostate cancer.
• 5:31
  You paste it onto some unfortunate mouse and then you
• 5:35
  treat it and see what happens. Now it's not human, but it's
• 5:39
  human cancers. All right, that's a step closer.
• 5:43
  Then you have case reports. These are individuals that are
• 5:49
  documented to have used a substance and have reported some
• 5:52
  benefit. Now that's a caution.
• 5:55
  If the only thing you see are testimonials and case reports,
• 6:00
  that's a red flag because if any a doctor like me has been in the
• 6:05
  arena for a while years, they should be able to report
• 6:10
  clusters of cohorts. These are pilot studies that can
• 6:16
  be produced and we have them in intellectual medicine for our
• 6:19
  prostate cancer people. You'll not see very many
• 6:23
  double-blind, placebo control long term studies because
• 6:28
  repurposed drugs are generic and they're cheap.
• 6:30
  So we like case reports. Then we like the pilot studies.
• 6:34
  These are small clusters of individuals in a controlled
• 6:37
  environment looking at outcomes. Of course, standardized
• 6:42
  double-blind studies are awesome, and when they're there,
• 6:46
  we take advantage of them. So what to watch out for?
• 6:50
  If you see a clinician, a Doctor Who has the same drug for
• 6:58
  everything, that's a problem. Cancer cells are multifaceted.
• 7:03
  They're not all the same. Some of them are androgen
• 7:06
  receptor positive, some not. Some of them will respond to
• 7:09
  drug X, some to drug Y. What we know about cancer in
• 7:14
  general and prostate cancer in particular is there's got to be
• 7:18
  synergy. You can't get there with one
• 7:22
  agent. I've seen some of these doctors
• 7:24
  online and it's like every problem has the same solution.
• 7:29
  Reminds me of that. My big fat Greek wedding.
• 7:31
  Remember the dad? Put Windex on it.
• 7:34
  You have a pimple? Put Windex on it.
• 7:36
  You have a headache? Put Windex on it.
• 7:38
  Sound familiar? You know they're out there.
• 7:41
  Another red flag. This is a disease state folks.
• 7:46
  This is not a do it yourself biohacking.
• 7:50
  Drop it off AI and the Internet and hope for the best.
• 7:53
  It's complex, multifaceted, added overlaps with other
• 7:58
  disease states, What the men with prostate cancer die from
• 8:03
  heart disease. Or if you're rendering therapy
• 8:06
  that is not sensitive to that fact, it could be
• 8:09
  counterproductive. What is needed, when is it
• 8:13
  needed, and what do you do if things progress?
• 8:16
  They all require collaboration with a knowledgeable clinician.
• 8:21
  Good news for you, I've finished training other nurse
• 8:26
  practitioners and physicians, family docs in my Petteruti
• 8:30
  protocol. That's good news for you.
• 8:32
  It's more access. So the protocol is not a rock
• 8:38
  solid carved in stone. Take this and let me see in a
• 8:42
  year. Has to be evaluated, has to be
• 8:46
  adaptable. The repurposed drugs are
• 8:48
  constantly being analyzed. But here are three of my
• 8:51
  favorites and I'll tell you why. All right.
• 8:54
  One of them is serilitis, also known as wrap immune
• 8:58
  prescription drug's been around for many years.
• 9:00
  It is used, the on label use is to suppress the immune system so
• 9:06
  that organs don't get rejected when they're transplanted.
• 9:10
  Hey, wait a minute, doc, you're going to say no, we don't
• 9:13
  suppress the immune system. That's the full dose everyday
• 9:17
  regimen. The low dose sporadically used
• 9:21
  has the opposite effect, cancer supportive.
• 9:25
  It blocks something called M Tor, mechanistic target of
• 9:29
  rapamycin, a natural substance. We all make too much of it and
• 9:34
  it pushes cancer cells into a reproductive cycle, partially
• 9:39
  blocking it. And you can interfere with
• 9:41
  cancer progression, especially for the prostate cancer that's
• 9:46
  isolated in the gland. I love this drug.
• 9:50
  I'm on it myself. It has collateral benefit,
• 9:53
  cellular anti aging, tissue regeneration, potentially
• 9:58
  extending lifespan. Yay.
• 10:01
  I'm all for that as long as I stay vertical, strong and clear
• 10:05
  of head. That's what I want for you guys.
• 10:07
  One study looking at circulating tumor cells treated with
• 10:11
  sirolimus had a reduction in tumor cells of 65.3% with no
• 10:17
  metastatic progression over the span of the study.
• 10:20
  Good information. Proof, Not really.
• 10:23
  But evidence, yes. In the world that we inhabit,
• 10:27
  folks, rock solid proof is hard to come by.
• 10:31
  There is in fact rock solid proof that conventional
• 10:36
  treatment, prostatectomy and radiation does not alter the
• 10:40
  death rate from metastatic prostate cancer compared to
• 10:44
  doing nothing. So it makes it an opening for us
• 10:47
  to think outside of the standard.
• 10:50
  How about another drug I like, low dose naltrexone.
• 10:54
  I love this drug. It's another one that's off
• 10:56
  label. The labeled use of naltrexone is
• 11:00
  to block endorphin receptors to diminish the impulsivity of
• 11:05
  opioid addicts to use their drug.
• 11:08
  Wait a minute, you think I'm an addict?
• 11:10
  No, the drug behaves completely differently.
• 11:13
  The technical term for this is a hermitic effect.
• 11:16
  Different effect at different doses.
• 11:19
  Low dose naltrexone blocks a synthesis of DNA in cancer
• 11:23
  cells. It helps to inhibit the capacity
• 11:25
  of cancer cells to migrate to metastasize.
• 11:29
  This is its purpose when it's used repurpose in a repurposed
• 11:33
  setting. Is there proof of benefit?
• 11:37
  No. Is there evidence of benefit?
• 11:40
  Yeah. Evidence.
• 11:41
  Is there collateral benefit? I use this drug often for people
• 11:45
  with chronic pain syndromes, fibromyalgia, muscle, tendon and
• 11:49
  joint. Well, as it so happens, men with
• 11:51
  prostate cancer typically are past 50 and they have some
• 11:55
  rusted joints, so you get some secondary benefit.
• 11:58
  I've had men come back to us and say, wow, you know, I just
• 12:00
  started to notice and my back doesn't hurt anymore.
• 12:04
  Yeah, it will take that. It also has anti-inflammatory
• 12:08
  attributes that can be utilized in cases of inflammatory bowel
• 12:11
  disease, Crohn's, ulcerative colitis.
• 12:13
  It's one of my standard approaches for people with
• 12:16
  autoimmune diseases. So collateral benefit, safety
• 12:21
  research based support of possible benefit.
• 12:23
  Check, check, check. Take a deep breath and don't
• 12:29
  throw tomatoes at me until I'm done talking.
• 12:33
  I don't like statin drugs for primary prevention of heart
• 12:36
  disease. They are ridiculously over
• 12:39
  promoted. And I don't like statin drugs
• 12:42
  for lowering cholesterol in the absence of some high.
• 12:45
  If you've had a heart attack, if you're a diabetic, if you've got
• 12:48
  horrible vascular disease, maybe.
• 12:51
  But the notion that your number is here and they want it to be
• 12:55
  here and we're going to give you a drug to make this number
• 12:57
  change occur, that is preposterous.
• 13:01
  That is made-up disease states to make you what come back to
• 13:05
  make you take a drug that isn't going to affect the outcome.
• 13:10
  So why am I talking about statin drugs and prostate cancer?
• 13:13
  Because they actually have a valuable role in this setting.
• 13:18
  Now, you know, functional guy like me, not crazy about statin
• 13:22
  drug, but I told you I'm an agnostic.
• 13:25
  I told you if it's good for my patients, you got to think about
• 13:28
  it. And guys and gals, statin drugs,
• 13:31
  check that box. They work through an interesting
• 13:35
  phenomenon called ferropoptosis. They help to impose iron
• 13:41
  molecules into cancer cells. Iron is harmful.
• 13:46
  Free iron molecules are pro inflammatory.
• 13:50
  Those of you that are out there, if you're taking an iron pill
• 13:53
  and you're not actively bleeding, think twice.
• 13:57
  Talk to your doctor. Do you really need that if
• 14:00
  you're getting an intravenous iron infusion because it's going
• 14:03
  to boost your energy? Oh goodness sakes, just stop.
• 14:07
  But if you have cancer, prostate cancer, the statins may have a
• 14:12
  niche. Now here's a combination.
• 14:15
  The synergy dynamic is at force here.
• 14:17
  Synergy is when 1 + 1 = 5. Two drugs together.
• 14:22
  More potent. We see synergy with Serilimus
• 14:25
  and Metformin combined. We see synergy with a statin and
• 14:29
  serilitis and metformin combined.
• 14:31
  In one study, 12,700 patients looking at the statin drug plus
• 14:37
  metformin. These are prostate cancer folks.
• 14:41
  There was a reduction in all 'cause mortality with no adverse
• 14:45
  side effect. Is it good for everybody?
• 14:49
  It is not. So some people can't take them.
• 14:52
  They cause side effects. That's true with any drug, and
• 14:56
  This is why you need to have a relationship with a clinician.
• 15:00
  If your relationship is simply ordering stuff online, you have
• 15:04
  a quack for a doc, right? And if your relationship is just
• 15:07
  you trying to figure it out, you got a quack for a doc.
• 15:11
  So be thoughtful. Avoid conventional treatment.
• 15:15
  The opportunity to consider an array of different approaches is
• 15:19
  out there. Book helps to outline some of
• 15:23
  the research behind it all. So although I like the three
• 15:28
  repurposed drugs I shared with you, there are several others
• 15:31
  time didn't permit me to highlight, but we will discuss
• 15:35
  them over time. What should you use, when should
• 15:38
  you use it, and how much collaborative decisions to be
• 15:42
  made? The process has to be analyzed.
• 15:46
  So repurposed drugs, I'm all for them in the arena of cancer.
• 15:53
  They can be used in some malignancies in a complementary
• 15:56
  fashion. What makes prostate cancer so
• 15:59
  utterly unique? It's not like any other cancer.
• 16:03
  You really can't apply things that work for other malignancies
• 16:07
  to the prostate. It's that different.
• 16:11
  We look for sustainability, and that has to be tolerance and no
• 16:16
  adverse side effects. As I've described.
• 16:18
  Some secondary benefits even better and then it's got to be
• 16:22
  cash flow affordable. If you want non conventional
• 16:27
  treatment for your prostate cancer, insurance isn't going to
• 16:31
  be there for you. Well, maybe a little bit right,
• 16:34
  but by and large this becomes your health priority.
• 16:39
  We're in an era of explosive advance in anti aging therapies,
• 16:44
  cellular rejuvenation, potential life extension.
• 16:49
  And none of it's going to happen with your Blue Cross card or
• 16:53
  your Medicare. That's sick insurance.
• 16:57
  That's what you'll use if everything else fails.
• 17:01
  So options, they're out there. You have to do the homework.
• 17:08
  This is not going to be something you can discuss with
• 17:10
  your conventional Dr. It's outside of the the boundaries of
• 17:14
  their fund of knowledge, right? We all have limited time and we
• 17:19
  all have accountability to others.
• 17:22
  If I'm JoJo, the oncologist I'm working for, Ex Health
• 17:27
  Incorporated, somebody's watching me and I can't talk
• 17:31
  outside of standard of care. I'll be punished.
• 17:35
  And the same holds true for surgeons, and the same holds
• 17:38
  true for a lot of primary care docs.
• 17:40
  They speak outside of the standard of care at their own
• 17:44
  risk. I know of what I speak.
• 17:47
  I'm a board certified family doctor.
• 17:49
  I don't take insurance because I don't want it to impose my
• 17:54
  freedom of thought. Anyhow, that's a little
• 17:58
  highlight. Repurposed drugs, yes.
• 18:01
  When and how and how much integrated.
• 18:03
  More information, of course, in that book.
• 18:06
  But the most important thing I can share with you men and the
• 18:09
  women who love them and the men who love them and everybody out
• 18:12
  there is you can't make a bad decision.
• 18:15
  It's your body, it's your life. My objective is to give more
• 18:20
  freedom of choice, not to tell you that if you don't do my
• 18:24
  protocol, you're a knucklehead and harm will come.
• 18:28
  Can't say that. There's too much unknown and
• 18:31
  only you know what's in your head and your heart.
• 18:34
  You go to bed every night with your prostate, with the cancer
• 18:37
  inside of it. What does that feel like?
• 18:41
  I know some men say, you know what, doc?
• 18:43
  I know the research doesn't support it, but by golly, I want
• 18:45
  to cut out. That's OK.
• 18:49
  As long as you're not misled, as long as they don't tell you it's
• 18:53
  secure because it's not. As long as they share with you
• 18:57
  other alternatives because they are now out there.
• 19:00
  All right, enough for me for one moment.
• 19:03
  Until the next time, folks. Thanks for watching my podcast.
• 19:06
  Look forward to seeing you on the next the next edition.
• 19:09
  Bye.